logo

For the Inventor, By the Inventor

San Diego, CA, United States of America

Nantkwest Inc.


USPTO Granted Patents = 17



Trademarks = 11

Forward Citations = 93

Loading Chart...
Loading Chart...

11 inventors (with patents filed for the assignee):

goldMedal Hans G Klingemann (14 out of 47 patents)

silverMedal Laurent H Boissel (9 out of 36 patents)

bronzeMedal Barry J Simon (7 out of 18 patents)

4.  Patrick Soon-Shiong (4 out of 476 patents)

5.  Tien Lee (4 out of 7 patents)

6.  John H Lee (2 out of 13 patents)

7.  Nathan T Schomer (2 out of 3 patents)

8.  Jeffrey Safrit (1 out of 5 patents)

9.  Abhijit Dandapat (1 out of 5 patents)

10.  Kayvan R Niazi (1 out of 101 patents)

11.  James N Woody (1 out of 2 patents)


17 patents:

1. 12427152 - HDAC inhibitors for use with NK cell based therapies (2025-09-30),
2. 12303477 - HIV treatment compositions and methods (2025-05-20),
3. 11077143 - Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-expressing NK cells (2021-08-03),
4. 11058723 - Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies (2021-07-13),
5. 11000550 - Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancer (2021-05-11),
6. 10960024 - Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies (2021-03-30),
7. 10801013 - Modified NK-92 haNK003 cells for the clinic (2020-10-13),
8. 10774310 - Modified NK-92 haNK003 cells for the clinic (2020-09-15),
9. 10772912 - Tumoricidal and antimicrobial composition (2020-09-15),
10. 10765701 - Elimination of CD19-positive lymphoid malignancies by CD19-CAR expressing NK cells (2020-09-08),
11. 10738279 - Modified NK-92 cells for treating cancer (2020-08-11),
12. 10736921 - Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancer (2020-08-11),
13. 10646516 - Tumoricidal and antimicrobial compositions and methods (2020-05-12),
14. 10517895 - Tumoricidal and antimicrobial compositions and methods (2019-12-31),
15. 10456420 - Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancer (2019-10-29),
Company Overview
Nantkwest Inc. is a biotechnology company based in San Diego, California, focused on developing innovative immunotherapy treatments for cancer and other diseases. The company specializes in harnessing the power of the immune system to create therapies that target and destroy malignant cells. Nantkwest's research emphasizes the use of natural killer (NK) cell technology, aiming to enhance the efficacy of cancer treatments while minimizing side effects. Their commitment to advancing healthcare solutions positions them as a key player in the biopharmaceutical landscape.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

17 Patents

#341 in San Diego, CA

#4,515 in California

#18,894 in US

#35,918 in the World

San Diego, CA (US)
San Diego, CA, United States of America

Nantkwest Inc.

Forward Citations = 93

11 inventors:

goldMedal Hans G Klingemann (14 out of 47 patents)

silverMedal Laurent H Boissel (9 out of 36 patents)

bronzeMedal Barry J Simon (7 out of 18 patents)

4.  Patrick Soon-Shiong (4 out of 476 patents)

5.  Tien Lee (4 out of 7 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Nantkwest Inc.. Retrieved from https://idiyas.com/company/nantkwest

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…